{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:35:50Z","timestamp":1793050550334,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR39858\/MED\/30\/2247\/2020"],"award-info":[{"award-number":["BT\/PR39858\/MED\/30\/2247\/2020"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Osteoporosis and Sarcopenia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.afos.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T07:54:46Z","timestamp":1679903686000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis"],"prefix":"10.1016","volume":"9","author":[{"given":"Akash","family":"Mitra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8485-7172","authenticated-orcid":false,"given":"Rizwan","family":"Qaisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipasha","family":"Bose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-8508","authenticated-orcid":false,"given":"Shenoy P","family":"Sudheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.afos.2023.03.008_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00223-014-9915-y","article-title":"Skeletal muscle: a brief review of structure and function","volume":"96","author":"Frontera","year":"2015","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.afos.2023.03.008_bib2","article-title":"Denervation drives skeletal muscle atrophy and induces mitochondrial dysfunction, mitophagy and apoptosis via miR-142a-5p\/MFN1 axis","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.afos.2023.03.008_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279261","article-title":"Sodium fluoride induces skeletal muscle atrophy via changes in mitochondrial and sarcomeric proteomes","volume":"17","author":"Nagendra","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.afos.2023.03.008_bib4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/j.cmet.2021.10.009","article-title":"Diabetes-induced skeletal muscle fibrosis: fibro-adipogenic precursors at work","volume":"33","author":"Chazaud","year":"2021","journal-title":"Cell Metabol"},{"key":"10.1016\/j.afos.2023.03.008_bib5","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/jcsm.12633","article-title":"Cancer cachexia and skeletal muscle atrophy in clinical studies: what do we really know?","volume":"11","author":"Dolly","year":"2020","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.afos.2023.03.008_bib6","first-page":"479","article-title":"Matrine improves skeletal muscle atrophy by inhibiting E3 ubiquitin ligases and activating the Akt\/mTOR\/FoxO3alpha signaling pathway in C2C12 myotubes and mice","volume":"42","author":"Chen","year":"2019","journal-title":"Oncol Rep"},{"key":"10.1016\/j.afos.2023.03.008_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2018.05.006","article-title":"Cancer cachexia: diagnosis, assessment, and treatment","volume":"127","author":"Sadeghi","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.afos.2023.03.008_bib8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1021\/jm501170d","article-title":"Identification of the minimum peptide from mouse myostatin prodomain for human myostatin inhibition","volume":"58","author":"Takayama","year":"2015","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.afos.2023.03.008_bib9","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/cas.14520","article-title":"Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia","volume":"111","author":"Ojima","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.afos.2023.03.008_bib10","first-page":"741","article-title":"Magnolol inhibits myotube atrophy induced by cancer cachexia through myostatin signaling pathway in\u00a0vitro","volume":"74","author":"Ge","year":"2020","journal-title":"J\u00a0Nat Med"},{"key":"10.1016\/j.afos.2023.03.008_bib11","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024186","article-title":"Association of myostatin, a cytokine released by muscle, with inflammation in rheumatoid arthritis: a cross-sectional study","volume":"100","author":"Murillo-Saich","year":"2021","journal-title":"Medicine (Baltimore"},{"key":"10.1016\/j.afos.2023.03.008_bib12","article-title":"Myostatin levels and the risk of myopenia and rheumatoid cachexia in women with rheumatoid arthritis","volume":"2022","author":"Gonzalez-Ponce","year":"2022","journal-title":"J\u00a0Immunol Res"},{"key":"10.1016\/j.afos.2023.03.008_bib13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180593","article-title":"Soluble activin type IIB receptor improves fracture healing in a closed tibial fracture mouse model","volume":"12","author":"Puolakkainen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.afos.2023.03.008_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/biof.1675","article-title":"Molecular basis and therapeutic potential of myostatin on bone formation and metabolism in orthopedic disease","volume":"49","author":"Cui","year":"2023","journal-title":"Biofactors"},{"key":"10.1016\/j.afos.2023.03.008_bib15","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.afos.2023.03.008_bib16","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.3389\/fimmu.2017.01747","article-title":"Myostatin promotes interleukin-1beta expression in rheumatoid arthritis synovial fibroblasts through inhibition of miR-21-5p","volume":"8","author":"Hu","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.afos.2023.03.008_bib17","doi-asserted-by":"crossref","first-page":"9793","DOI":"10.1002\/jcp.27665","article-title":"Myostatin induces tumor necrosis factor-alpha expression in rheumatoid arthritis synovial fibroblasts through the PI3K-Akt signaling pathway","volume":"234","author":"Su","year":"2019","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.afos.2023.03.008_bib18","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/nm.3917","article-title":"Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice","volume":"21","author":"Dankbar","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.afos.2023.03.008_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-93599-6","article-title":"A\u00a0myostatin-CCL20-CCR6 axis regulates Th17 cell recruitment to inflamed joints in experimental arthritis","volume":"11","author":"Fennen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2023.03.008_bib20","doi-asserted-by":"crossref","first-page":"E790","DOI":"10.1152\/ajpendo.00590.2010","article-title":"Fenofibrate, a PPARalpha agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy","volume":"300","author":"Castillero","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.afos.2023.03.008_bib21","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/j.bone.2007.02.012","article-title":"Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading","volume":"40","author":"Hamrick","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.afos.2023.03.008_bib22","first-page":"258","article-title":"MicroRNA in myogenesis and muscle atrophy","volume":"16","author":"Wang","year":"2013","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.afos.2023.03.008_bib23","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20110634","article-title":"microRNAs in skeletal muscle differentiation and disease","volume":"123","author":"Goljanek-Whysall","year":"2012","journal-title":"Clin Sci"},{"key":"10.1016\/j.afos.2023.03.008_bib24","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10834","article-title":"Maintenance of muscle stem-cell quiescence by microRNA-489","volume":"482","author":"Cheung","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.afos.2023.03.008_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ydbio.2007.08.032","article-title":"Essential role for Dicer during skeletal muscle development","volume":"311","author":"O'Rourke","year":"2007","journal-title":"Dev Biol"},{"key":"10.1016\/j.afos.2023.03.008_bib26","article-title":"Inhibition of miR-29 by TGF-beta-Smad3 signaling through dual mechanisms promotes transdifferentiation of mouse myoblasts into myofibroblasts","volume":"7","author":"Zhou","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.afos.2023.03.008_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbrc.2015.03.150","article-title":"Myostatin regulates miR-431 expression via the Ras-Mek-Erk signaling pathway","volume":"461","author":"Wu","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.afos.2023.03.008_bib28","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1038\/ncomms8713","article-title":"MicroRNA-431 accelerates muscle regeneration and ameliorates muscular dystrophy by targeting Pax7 in mice","volume":"6","author":"Wu","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.afos.2023.03.008_bib29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cbin.10192","article-title":"Role of microRNA-27a in myoblast differentiation","volume":"38","author":"Chen","year":"2014","journal-title":"Cell Biol Int"},{"key":"10.1016\/j.afos.2023.03.008_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbrc.2012.05.106","article-title":"MicroRNA-27a promotes myoblast proliferation by targeting myostatin","volume":"423","author":"Huang","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.afos.2023.03.008_bib31","doi-asserted-by":"crossref","first-page":"C124","DOI":"10.1152\/ajpcell.00142.2010","article-title":"Posttranscriptional mechanisms involving microRNA-27a and b contribute to fast-specific and glucocorticoid-mediated myostatin expression in skeletal muscle","volume":"300","author":"Allen","year":"2011","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.afos.2023.03.008_bib32","first-page":"10","article-title":"MicroRNA-27b-3p targets the myostatin gene to regulate myoblast proliferation and is involved in myoblast differentiation","author":"Zhang","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.afos.2023.03.008_bib33","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/bonekey.2016.48","article-title":"Effects of myokines on bone","volume":"5","author":"Kaji","year":"2016","journal-title":"BoneKEy Rep"},{"key":"10.1016\/j.afos.2023.03.008_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/456348","article-title":"Muscular dystrophy: disease mechanisms and therapies","volume":"2015","author":"Pandey","year":"2015","journal-title":"BioMed Res Int"},{"issue":"17","key":"10.1016\/j.afos.2023.03.008_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143737","article-title":"IRE1alpha regulates skeletal muscle regeneration through Myostatin mRNA decay","volume":"131","author":"He","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.afos.2023.03.008_bib36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1542\/peds.2014-2044","article-title":"Prevalence of Duchenne and becker muscular dystrophies in the United States","volume":"135","author":"Romitti","year":"2015","journal-title":"Pediatrics"},{"issue":"9","key":"10.1016\/j.afos.2023.03.008_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10090713","article-title":"MiRNAs, Myostatin, and muscle MRI imaging as biomarkers of clinical features in Becker muscular dystrophy","volume":"10","author":"Marozzo","year":"2020","journal-title":"Diagnostics"},{"issue":"10","key":"10.1016\/j.afos.2023.03.008_bib38","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1007\/s10072-020-04409-2","article-title":"MyomiRNAs and myostatin as physical rehabilitation biomarkers for myotonic dystrophy","volume":"41","author":"Pegoraro","year":"2020","journal-title":"Neurol Sci"},{"key":"10.1016\/j.afos.2023.03.008_bib39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0000000000000853","article-title":"The elusive promise of myostatin inhibition for muscular dystrophy","volume":"33","author":"Wagner","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.afos.2023.03.008_bib40","first-page":"151","article-title":"Myostatin Inhibitors: panacea or predicament for musculoskeletal disorders?","volume":"27","author":"Suh","year":"2020","journal-title":"J\u00a0Bone Metab"},{"key":"10.1016\/j.afos.2023.03.008_bib41","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000356740","article-title":"Myostatin and sarcopenia: opportunities and challenges - a mini-review","volume":"60","author":"White","year":"2014","journal-title":"Gerontology"},{"key":"10.1016\/j.afos.2023.03.008_bib42","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1210\/jc.2014-3290","article-title":"Myostatin inhibition: a new treatment for androgen deprivation-induced sarcopenia?","volume":"99","author":"Grossmann","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.afos.2023.03.008_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1474-9726.2009.00508.x","article-title":"Effects of myostatin deletion in aging mice","volume":"8","author":"Morissette","year":"2009","journal-title":"Aging Cell"},{"key":"10.1016\/j.afos.2023.03.008_bib44","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.2337\/db09-0349","article-title":"Genetic disruption of myostatin reduces the development of proatherogenic dyslipidemia and atherogenic lesions in Ldlr null mice","volume":"58","author":"Tu","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.afos.2023.03.008_bib45","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2337\/db08-0245","article-title":"Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance","volume":"58","author":"Wilkes","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.afos.2023.03.008_bib46","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/mus.25268","article-title":"Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial","volume":"55","author":"Campbell","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.afos.2023.03.008_bib47","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1073\/pnas.1916034117","article-title":"GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN\/GDF11 inhibitor, increases muscle mass but weakens bone","volume":"117","author":"Suh","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.afos.2023.03.008_bib48","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/nature01154","article-title":"Functional improvement of dystrophic muscle by myostatin blockade","volume":"420","author":"Bogdanovich","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.afos.2023.03.008_bib49","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13395-017-0141-y","volume":"7","author":"St Andre","year":"2017","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.afos.2023.03.008_bib50","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/cpdd.386","article-title":"Safety, Tolerability, pharmacokinetics, and pharmacodynamics of domagrozumab (pf-06252616), an antimyostatin monoclonal antibody, in healthy subjects","volume":"7","author":"Bhattacharya","year":"2018","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.afos.2023.03.008_bib51","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/dta.2729","article-title":"Detection of the myostatin-neutralizing antibody Domagrozumab in serum by means of Western blotting and LC-HRMS","volume":"11","author":"Walpurgis","year":"2019","journal-title":"Drug Test Anal"},{"key":"10.1016\/j.afos.2023.03.008_bib52","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1096\/fj.10-176917","article-title":"Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease","volume":"25","author":"Zhang","year":"2011","journal-title":"Faseb J"},{"key":"10.1016\/j.afos.2023.03.008_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-13912-0","article-title":"Pharmacological inhibition of myostatin improves skeletal muscle mass and function in a mouse model of stroke","volume":"7","author":"Desgeorges","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2023.03.008_bib54","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13395-015-0060-8","article-title":"Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice","volume":"5","author":"Latres","year":"2015","journal-title":"Skeletal Muscle"},{"key":"10.1016\/j.afos.2023.03.008_bib55","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/hmg\/ddy382","article-title":"Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy","volume":"28","author":"Long","year":"2019","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.afos.2023.03.008_bib56","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/mus.23539","article-title":"A\u00a0single ascending-dose study of muscle regulator ACE-031 in healthy volunteers","volume":"47","author":"Attie","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.afos.2023.03.008_bib57","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/mus.26113","article-title":"Locally acting ACE-083 increases muscle volume in healthy volunteers","volume":"57","author":"Glasser","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.afos.2023.03.008_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47818-w","article-title":"Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease","volume":"9","author":"Pearsall","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.afos.2023.03.008_bib59","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1212\/WNL.0000000000001070","article-title":"Treatment of sporadic inclusion body myositis with bimagrumab","volume":"83","author":"Amato","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.afos.2023.03.008_bib60","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(19)30200-5","article-title":"Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Hanna","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.afos.2023.03.008_bib61","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jgs.14927","article-title":"Treatment of sarcopenia with bimagrumab: results from a phase ii, randomized, controlled, proof-of-concept study","volume":"65","author":"Rooks","year":"2017","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.afos.2023.03.008_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/jcsm.12205","article-title":"Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy","volume":"8","author":"Rooks","year":"2017","journal-title":"J\u00a0Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.afos.2023.03.008_bib63","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1164\/rccm.201802-0286OC","article-title":"Activin type ii receptor blockade for treatment of muscle depletion in chronic obstructive pulmonary disease. A randomized trial","volume":"199","author":"Polkey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.afos.2023.03.008_bib64","doi-asserted-by":"crossref","first-page":"6ra15","DOI":"10.1126\/scitranslmed.3000112","article-title":"Follistatin gene delivery enhances muscle growth and strength in nonhuman primates","volume":"1","author":"Kota","year":"2009","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.afos.2023.03.008_bib65","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/mt.2014.200","article-title":"A\u00a0phase 1\/2a follistatin gene therapy trial for becker muscular dystrophy","volume":"23","author":"Mendell","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.afos.2023.03.008_bib66","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ymthe.2017.02.015","article-title":"Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes","volume":"25","author":"Mendell","year":"2017","journal-title":"Mol Ther"},{"issue":"19","key":"10.1016\/j.afos.2023.03.008_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231912039","article-title":"Nanomedicine for treating muscle dystrophies: opportunities, challenges, and future perspectives","volume":"23","author":"Ahmed","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.afos.2023.03.008_bib68","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/s41598-018-20524-9","article-title":"Blocking extracellular activation of myostatin as a strategy for treating muscle wasting","volume":"8","author":"Pirruccello-Straub","year":"2018","journal-title":"Sci Rep"}],"container-title":["Osteoporosis and Sarcopenia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525523000092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405525523000092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:35:27Z","timestamp":1762500927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405525523000092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S2405525523000092"],"URL":"https:\/\/doi.org\/10.1016\/j.afos.2023.03.008","relation":{},"ISSN":["2405-5255"],"issn-type":[{"value":"2405-5255","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis","name":"articletitle","label":"Article Title"},{"value":"Osteoporosis and Sarcopenia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.afos.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Korean Society of Osteoporosis. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}